Cargando…
Enantiomer‐specific pharmacokinetics of D,L‐3‐hydroxybutyrate: Implications for the treatment of multiple acyl‐CoA dehydrogenase deficiency
D,L‐3‐hydroxybutyrate (D,L‐3‐HB, a ketone body) treatment has been described in several inborn errors of metabolism, including multiple acyl‐CoA dehydrogenase deficiency (MADD; glutaric aciduria type II). We aimed to improve the understanding of enantiomer‐specific pharmacokinetics of D,L‐3‐HB. Usin...
Autores principales: | van Rijt, Willemijn J., Van Hove, Johan L. K., Vaz, Frédéric M., Havinga, Rick, Allersma, Derk P., Zijp, Tanja R., Bedoyan, Jirair K., Heiner‐Fokkema, M. R., Reijngoud, Dirk‐Jan, Geraghty, Michael T., Wanders, Ronald J. A., Oosterveer, Maaike H., Derks, Terry G. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359440/ https://www.ncbi.nlm.nih.gov/pubmed/33543789 http://dx.doi.org/10.1002/jimd.12365 |
Ejemplares similares
-
Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency
por: van Rijt, Willemijn J., et al.
Publicado: (2020) -
Plasma carnitine concentrations in Medium‐chain acyl‐CoA dehydrogenase deficiency: lessons from an observational cohort study
por: Jager, Emmalie A., et al.
Publicado: (2022) -
Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency
por: van Maldegem, Bianca T., et al.
Publicado: (2010) -
In vitro and in vivo consequences of variant medium-chain acyl-CoA dehydrogenase genotypes
por: Touw, Catharina ML, et al.
Publicado: (2013) -
The role of the acyl-CoA thioesterase “YciA” in the production of (R)-3-hydroxybutyrate by recombinant Escherichia coli
por: Guevara-Martínez, Mónica, et al.
Publicado: (2019)